Future cardiology最新文献_第3页

Pulmonary hypertension associated with sarcoidosis: current and future treatment landscape. 结节病相关的肺动脉高压：当前和未来的治疗前景。

IF 1

Future cardiology Pub Date : 2025-08-19 DOI: 10.1080/14796678.2025.2549173

Giordano Fiorentù, Nicol Bernardinello, Laura De Michieli, Martina Perazzolo Marra, Elisabetta Balestro, Paolo Spagnolo

引用次数: 0

Pregnancy with prosthetic heart valves: navigating risks, anticoagulation, and valve function in a growing population. 妊娠与人工心脏瓣膜：导航风险，抗凝血和瓣膜功能在不断增长的人口。

IF 1

Future cardiology Pub Date : 2025-08-16 DOI: 10.1080/14796678.2025.2548152

Ishani Joshi, Jonathan Buber

{"title":"Pregnancy with prosthetic heart valves: navigating risks, anticoagulation, and valve function in a growing population.","authors":"Ishani Joshi, Jonathan Buber","doi":"10.1080/14796678.2025.2548152","DOIUrl":"https://doi.org/10.1080/14796678.2025.2548152","url":null,"abstract":"Pregnancy in patients with prosthetic heart valves presents complex challenges requiring multidisciplinary care and individualized decision-making. While bioprosthetic valves are often preferred in women of childbearing age to avoid anticoagulation-related fetal risks, these valves are susceptible to structural degeneration potentially accelerated by the physiologic demands of pregnancy. Conversely, mechanical valves offer durability but necessitate lifelong anticoagulation, posing substantial risks of valve thrombosis, fetal hemorrhage, and warfarin embryopathy. The Ross operation, which can be considered for individuals with advanced aortic valve disease, is an appealing option yet is offered only in highly specialized centers. In this review, we present contemporary data on maternal and fetal outcomes, valve function, and anticoagulation strategies in pregnant patients with mechanical and bioprosthetic heart valves. We highlight geographical and knowledge gaps regarding type of valve utilization, optimal anticoagulation in pregnancy, durability of modern valve designs, and long-term reoperation risk. Future research priorities include uniform global approach with improved access to contemporary surgical and medical solutions in low- and middle-income countries, safety of direct oral anticoagulants, improved surveillance of valve function during pregnancy, and comparative studies of bioprosthetic valve models. By consolidating evolving evidence, we aim to support informed decision-making and multidisciplinary management for this high-risk patient population.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-6"},"PeriodicalIF":1.0,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute myocardial infarction treatment delay in South Asia: a systematic review and meta-analysis. 南亚急性心肌梗死治疗延迟：系统回顾和荟萃分析。

IF 1

Future cardiology Pub Date : 2025-08-14 DOI: 10.1080/14796678.2025.2541525

Deepthi Ramamurthy, Meely Panda, Manjula Rangappa, Suthanthira Kannan, Rashmi Kundapur, Swetha Rajeshwari, Padmavathi Subbiah, Pradeep Aggarwal, Sumit Aggarwal

{"title":"Acute myocardial infarction treatment delay in South Asia: a systematic review and meta-analysis.","authors":"Deepthi Ramamurthy, Meely Panda, Manjula Rangappa, Suthanthira Kannan, Rashmi Kundapur, Swetha Rajeshwari, Padmavathi Subbiah, Pradeep Aggarwal, Sumit Aggarwal","doi":"10.1080/14796678.2025.2541525","DOIUrl":"10.1080/14796678.2025.2541525","url":null,"abstract":"Background: Acute Myocardial Infarction (AMI) necessitates timely treatment to improve outcomes. Identifying treatment delays across different South Asian countries can aid in formulating policies to reduce these delays. Objectives: To estimate the average treatment delay in AMI patients in South Asia and identify contributing factors.Methods: Using the CoCoPop framework (Condition, Context, Population), studies were reviewed on AMI treatment delays in South Asia from 2000 to 2022. Databases searched included PubMed Central, Embase and Google Scholar. Eligible studies were cross-sectional and analytical that reported exact delay times, excluding knowledge, attitude, practice studies, narrative reviews, and case reports.Results: The search yielded 2954 records, with 42 studies meeting the inclusion criteria. The pooled median prehospital delay was 531 minutes (95% CI: 366-769 minutes). The pooled mean door-to-ECG time was 9.18 minutes (95% CI: 2.52-15.84 minutes). The door-to-needle and door to balloon time among STEMI patients were 37.95 (95% CI: 30.11-45.78 minutes) minutes and 62.92 minutes (95% CI: 45.28-80.56 minutes), respectively with significant heterogeneity. Factors associated with delays included old age, female gender, low literacy, ignorance, financial constraints, and rural location.Conclusion: Significant treatment delays for AMI patients in South Asia are identified, with socio-economic and logistical barriers contributing to these delays.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-15"},"PeriodicalIF":1.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144845467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atrial cardiomyopathy: current clinical perspectives and future insights. 心房心肌病：目前的临床观点和未来的见解。

IF 1

Future cardiology Pub Date : 2025-08-14 DOI: 10.1080/14796678.2025.2548159

Moh'd Alamin Daise, Geran Maule, Mohamed Ismail, Qusai Alqudah, Sanaullah Mojaddedi, Omar Obeidat, Khaled Ismail

{"title":"Atrial cardiomyopathy: current clinical perspectives and future insights.","authors":"Moh'd Alamin Daise, Geran Maule, Mohamed Ismail, Qusai Alqudah, Sanaullah Mojaddedi, Omar Obeidat, Khaled Ismail","doi":"10.1080/14796678.2025.2548159","DOIUrl":"https://doi.org/10.1080/14796678.2025.2548159","url":null,"abstract":"Atrial cardiomyopathy (ACM) is an underrecognized cardiac entity marked by structural, contractile, or electrophysiological changes in the atria, yet it lacks established clinical diagnostic criteria and management guidelines. These alterations - driven by molecular, mechanical, and genetic factors - lead to atrial remodeling and contribute to arrhythmogenesis, thromboembolic complications, and the progression of heart failure. Despite recent advances in imaging, biomarkers, and histopathological classifications, the pathophysiology of ACM remains complex and multifactorial, involving processes such as inflammation, oxidative stress, and genetic predisposition. This review synthesizes current knowledge on ACM, including its classification, pathophysiologic mechanisms, and clinical relevance in atrial fibrillation, ischemic stroke, and heart failure with preserved ejection fraction (HFpEF). We also explore emerging diagnostic tools and biomarkers that may aid in risk stratification and therapeutic decision-making. Ultimately, we aim to underscore the clinical significance of ACM and advocate for the development of standardized diagnostic frameworks and personalized treatment strategies to improve patient outcomes.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-9"},"PeriodicalIF":1.0,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Postpartum cardiomyopathy with severe complications: multimodal management and long-term recovery. 产后严重并发症心肌病：多模式管理和长期恢复。

IF 1

Future cardiology Pub Date : 2025-08-11 DOI: 10.1080/14796678.2025.2543677

Mariola Szulik, Katarzyna Mykieta, Natasza Millan, Alexander Suchodolski

引用次数: 0

Tricuspid valve edge to edge repair vs replacement - a comparative analysis and future directions. 三尖瓣边缘修复与置换的比较分析及未来发展方向。

IF 1

Future cardiology Pub Date : 2025-08-08 DOI: 10.1080/14796678.2025.2545133

Joseph Hajj, Joseph Kassab, Ziad Zalaquett, Serge C Harb, Samir R Kapadia

{"title":"Tricuspid valve edge to edge repair vs replacement - a comparative analysis and future directions.","authors":"Joseph Hajj, Joseph Kassab, Ziad Zalaquett, Serge C Harb, Samir R Kapadia","doi":"10.1080/14796678.2025.2545133","DOIUrl":"https://doi.org/10.1080/14796678.2025.2545133","url":null,"abstract":"Tricuspid regurgitation (TR) is a common yet underrecognized valvular disease associated with significant morbidity and mortality. Recent advances in transcatheter therapies, namely transcatheter edge-to-edge repair (T-TEER) with the TriClip device (Abbott) and transcatheter tricuspid valve replacement (TTVR) with the EVOQUE device (Edwards Lifesciences), offer promising alternatives to surgery for severe symptomatic TR. This review compares both approaches with a focus on safety, procedural considerations, and clinical outcomes. Treating TR remains uniquely challenging due to the anatomical complexity of the valve, frequent lead interference, and common coexistence of RV dysfunction, atrial fibrillation, and pulmonary hypertension. Many affected patients are elderly and frail, rendering them poor surgical candidates. Optimal treatment requires individualized decision-making guided by detailed imaging and assessment of RV function and valvular anatomy. Both therapies achieve significant TR reduction, yet each carries distinct risks: TTVR is associated with higher rates of pacemaker implantation, bleeding, and RV failure, while T-TEER may lead to single leaflet device attachment (SLDA), leaflet injury, or residual TR. Careful patient selection is essential. Despite encouraging short-term outcomes, long-term data are needed to determine survival benefit and durability. Further studies are warranted to refine technique and optimize candidate selection.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-12"},"PeriodicalIF":1.0,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144798821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Up-to-date review on concomitant mitral transcatheter edge-to-edge repair and left atrial appendage occlusion. 二尖瓣经导管边缘对边缘修复和左心耳闭塞术的最新研究进展。

IF 1

Future cardiology Pub Date : 2025-08-04 DOI: 10.1080/14796678.2025.2543184

Graeme Prosperi-Porta, Abdullah Al-Abcha, Trevor Simard, Benjamin Hibbert, Omar Abdel-Razek

{"title":"Up-to-date review on concomitant mitral transcatheter edge-to-edge repair and left atrial appendage occlusion.","authors":"Graeme Prosperi-Porta, Abdullah Al-Abcha, Trevor Simard, Benjamin Hibbert, Omar Abdel-Razek","doi":"10.1080/14796678.2025.2543184","DOIUrl":"https://doi.org/10.1080/14796678.2025.2543184","url":null,"abstract":"In patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER), atrial fibrillation is a common comorbidity. While oral anticoagulation is the mainstay of stroke prevention therapy in most patients with atrial fibrillation, patients undergoing M-TEER might have a unique opportunity to undergo concomitant left atrial appendage occlusion (LAAO). LAAO is an alternative to oral anticoagulation that reduces the long-term risk of stroke and major bleeding, but it comes with upfront peri-procedural risk. M-TEER and LAAO share numerous procedural characteristics including large-bore venous access, transseptal puncture, general anesthesia, and real-time imaging of the left atrium with echocardiography. Therefore, performing concomitant LAAO at the time of M-TEER might be an attractive option for patients to lessen the cumulative peri-procedural risk, repeated anesthetic, and hospital visits from separate procedures. With rapidly evolving device technologies and an increasing evidence base for LAAO use, there is still limited data evaluating the safety and feasibility of concomitant M-TEER and LAAO. This up-to-date narrative review on concomitant M-TEER and LAAO aims to summarize the current body of literature, review practical procedural considerations, and review the unmet research questions limiting the widespread adoption of this concomitant intervention.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"1-9"},"PeriodicalIF":1.0,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Device longevity of a leadless pacemaker family. 无导线起搏器系列的设备寿命。

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-07-16 DOI: 10.1080/14796678.2025.2527466

Miguel A Leal, Todd Sheldon, Keelia Escalante, Mikayle Holm, Michelle Galarneau, Sarah Rosemas, Kurt Stromberg, Jonathan P Piccini

{"title":"Device longevity of a leadless pacemaker family.","authors":"Miguel A Leal, Todd Sheldon, Keelia Escalante, Mikayle Holm, Michelle Galarneau, Sarah Rosemas, Kurt Stromberg, Jonathan P Piccini","doi":"10.1080/14796678.2025.2527466","DOIUrl":"10.1080/14796678.2025.2527466","url":null,"abstract":"Background: Leadless ventricular pacemakers have been developed for single chamber VVIR and AV synchronous pacing applications.Aim: To assess the device longevity impact of battery/electronics enhancements of next-generation Micra leadless pacemakers, Micra VR2 and AV2, compared to Micra VR and AV.Methods: Real-world pacing data gathered from the Micra IDE study, Medtronic's CareLink database, and historical pacemaker patient survival data from Medtronic's Device Registry were used to project device longevity and estimate the proportion of patients requiring lifetime device replacements.Results: Based on data from 644 patients, the median projected longevity of Micra VR was 12.3 years and Micra VR2 was 16.7 years, with 91% of patients requiring a single VR2 device over their lifetime. Based on data from 999 patients, the median projected longevity of Micra AV was 10.8 years and Micra AV2 was 15.6 years, with 80% of patients requiring one AV2 device. The longevity improvements with Micra VR2 projected 8 fewer device replacements would be required across 100 patients. Similarly, 15 devices would be avoided when considering Micra AV versus AV2.Conclusions: Modeling of the Micra leadless pacemakers projected meaningful improvements in device longevity and an increase in the number of patients served with a single device.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"753-758"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary antiarrhythmic pharmacotherapy: revisiting the old, exploring the new. 当代抗心律失常药物治疗：重访旧，探索新。

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-07-15 DOI: 10.1080/14796678.2025.2534323

Stefan Totolici, Raluca Popescu, G-Andrei Dan

引用次数: 0

Concurrent aortic stenosis and hypertension: mortality trends in US older adults from 1999-2020. 并发主动脉瓣狭窄和高血压：1999-2020年美国老年人死亡率趋势

IF 1

Future cardiology Pub Date : 2025-08-01 Epub Date: 2025-07-21 DOI: 10.1080/14796678.2025.2530906

Ahmed Raza, Fnu Kalpina, Manayiel Rehmat, Eman Alamgir, Eiman Zeeshan, Mateen Ahmad, Moeen Ikram, Mustafa Turkmani, Ubaid Khan

{"title":"Concurrent aortic stenosis and hypertension: mortality trends in US older adults from 1999-2020.","authors":"Ahmed Raza, Fnu Kalpina, Manayiel Rehmat, Eman Alamgir, Eiman Zeeshan, Mateen Ahmad, Moeen Ikram, Mustafa Turkmani, Ubaid Khan","doi":"10.1080/14796678.2025.2530906","DOIUrl":"10.1080/14796678.2025.2530906","url":null,"abstract":"Background: Aortic Stenosis (AS) is a valvular heart disease. Hypertension accelerates stenosis, increasing morbidity and mortality. This study investigates mortality trends in US older adults with AS and hypertension from 1999 to 2020.Methods: Using the CDC WONDER database, age-adjusted mortality rates (AAMRs) per 100,000 individuals aged 65+ with AS and hypertension were analyzed. Changes in AAMRs were examined through annual percent change (APC) and average APC (AAPC) using Joinpoint regression.Results: From 1999 to 2020, hypertension caused 99,250 deaths in AS patients in the US, demonstrating an increasing trend (AAPC: 5.51%). Males had higher AAMRs (11.51) than females (9.99). Non-Hispanic (NH) white people (11.32) had the highest AAMRs, followed by Hispanic (7.37), NH Black people (7.27), and NH Asians (6.12). Regionally, the West showed the highest AAMR (13.3), followed by the Midwest (11.38), the Northeast (10.62), and the South (8.53). The states with the highest AAMRs were Vermont and Oregon, while Alabama and Georgia had the lowest. Non-metropolitan areas (11.19) experienced higher mortality than metropolitan areas (10.49).Conclusion: We report increasing mortality rates in patients with AS and hypertension, especially in males, NH white people, and the West. Target healthcare measures are needed to address the rising mortality.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"769-778"},"PeriodicalIF":1.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0